Novo Nordisk cuts its forecasts after a boom in copycats and the rise of Mounjaro
Novo Nordisk cuts its forecasts after a boom in copycats and the rise of Mounjaro
Copy link
Novo Nordisk files 14 lawsuits in US against companies selling duplicate drugs
A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain its…
Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug market
Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to…
Novo Nordisk insists its decision is unrelated to pressure from the US president
Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition
Crollo di Novo Nordisk, la concorrenza e le strategie di prezzo mettono a rischio il colosso dei farmaci per la perdita di peso
